Notes
Support for this study was provided by Boehringer Ingelheim Pharmaceuticals, Inc.
Reference
Ghosh S, et al. Predictors of Healthcare Costs After Initiating Dabigatran Versus Warfarin. American Journal of Pharmacy Benefits : 2 Feb 2018. Available from: URL: http://www.ajpb.com/journals/ajpb/2018/ajpb_januaryfebruary2018
Rights and permissions
About this article
Cite this article
Dabigatran vs warfarin in NVAF: ERG risk score predicts cost. PharmacoEcon Outcomes News 797, 12 (2018). https://doi.org/10.1007/s40274-018-4721-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4721-9